| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13489* | 2021 |
| Stat3 as an oncogene JF Bromberg, MH Wrzeszczynska, G Devgan, Y Zhao, RG Pestell, ... Cell 98 (3), 295-303, 1999 | 3723 | 1999 |
| The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway M Shtutman, J Zhurinsky, I Simcha, C Albanese, M D’Amico, R Pestell, ... Proceedings of the National Academy of Sciences 96 (10), 5522-5527, 1999 | 2889 | 1999 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2557 | 2019 |
| NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1 DC Guttridge, C Albanese, JY Reuther, RG Pestell, AS Baldwin Jr Molecular and cellular biology, 1999 | 1767 | 1999 |
| The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma S Pavlides, D Whitaker-Menezes, R Castello-Cros, N Flomenberg, ... Cell cycle 8 (23), 3984-4001, 2009 | 1561 | 2009 |
| Cancer metabolism: a therapeutic perspective UE Martinez-Outschoorn, M Peiris-Pagés, RG Pestell, F Sotgia, ... Nature reviews Clinical oncology 14 (1), 11-31, 2017 | 1521 | 2017 |
| Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities B Razani, JA Engelman, XB Wang, W Schubert, XL Zhang, CB Marks, ... Journal of Biological Chemistry 276 (41), 38121-38138, 2001 | 1409 | 2001 |
| Minireview: Cyclin D1: normal and abnormal functions M Fu, C Wang, Z Li, T Sakamaki, RG Pestell Endocrinology 145 (12), 5439-5447, 2004 | 1278 | 2004 |
| Transforming p21ras mutants and c-ets-2 activate the cyclin d1 promoter through distinguishable regions (∗) C Albanese, J Johnson, G Watanabe, N Eklund, D Vu, A Arnold, ... Journal of Biological Chemistry 270 (40), 23589-23597, 1995 | 1078 | 1995 |
| β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression SY Lin, W Xia, JC Wang, KY Kwong, B Spohn, Y Wen, RG Pestell, ... Proceedings of the National Academy of Sciences 97 (8), 4262-4266, 2000 | 1054 | 2000 |
| Cancer stem cells Z Yu, TG Pestell, MP Lisanti, RG Pestell The international journal of biochemistry & cell biology 44 (12), 2144-2151, 2012 | 868 | 2012 |
| Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes L Galluzzi, SA Aaronson, J Abrams, ES Alnemri, DW Andrews, ... Cell Death & Differentiation 16 (8), 1093-1107, 2009 | 856 | 2009 |
| Ketones and lactate “fuel” tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism G Bonuccelli, A Tsirigos, D Whitaker-Menezes, S Pavlides, RG Pestell, ... Cell cycle 9 (17), 3506-3514, 2010 | 715 | 2010 |
| BRCA1 inhibition of estrogen receptor signaling in transfected cells S Fan, JA Wang, R Yuan, Y Ma, Q Meng, MR Erdos, RG Pestell, F Yuan, ... Science 284 (5418), 1354-1356, 1999 | 664 | 1999 |
| The mammary gland iodide transporter is expressed during lactation and in breast cancer UH Tazebay, IL Wapnir, O Levy, O Dohan, LS Zuckier, Q Hua Zhao, ... Nature medicine 6 (8), 871-878, 2000 | 642 | 2000 |
| Targeted downregulation of caveolin‐1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade F Galbiati, D Volonté, JA Engelman, G Watanabe, R Burk, RG Pestell, ... The EMBO journal, 1998 | 638 | 1998 |
| The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation L Shivakumar, J Minna, T Sakamaki, R Pestell, MA White Molecular and cellular biology 22 (12), 4309-4318, 2002 | 608 | 2002 |
| Opposing action of estrogen receptors α and β on cyclin D1 gene expression MM Liu, C Albanese, CM Anderson, K Hilty, P Webb, RM Uht, RH Price, ... Journal of Biological Chemistry 277 (27), 24353-24360, 2002 | 604 | 2002 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 593 | 2019 |